Zacks Investment Research lowered shares of Evolus (NASDAQ:EOLS) from a hold rating to a sell rating in a research note issued to investors on Tuesday.

According to Zacks, “Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. “

Separately, Cantor Fitzgerald set a $35.00 price target on Evolus and gave the stock a buy rating in a research note on Thursday, September 27th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $30.40.

Shares of Evolus stock traded up $0.04 during midday trading on Tuesday, reaching $16.00. 1,491 shares of the company’s stock traded hands, compared to its average volume of 336,931. The company has a market cap of $444.04 million and a PE ratio of -59.11. Evolus has a 12 month low of $6.75 and a 12 month high of $39.50.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings results on Monday, November 5th. The company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.09). On average, equities analysts predict that Evolus will post -1.84 EPS for the current year.

In related news, Director David N. Gill bought 3,000 shares of the business’s stock in a transaction dated Friday, December 14th. The shares were purchased at an average cost of $12.77 per share, with a total value of $38,310.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Vikram Malik bought 7,800 shares of the business’s stock in a transaction dated Monday, December 17th. The stock was bought at an average cost of $13.04 per share, for a total transaction of $101,712.00. The disclosure for this purchase can be found here. Over the last three months, insiders bought 17,147 shares of company stock worth $228,880.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EOLS. SG Americas Securities LLC purchased a new stake in shares of Evolus in the second quarter worth $108,000. Wells Fargo & Company MN grew its stake in shares of Evolus by 860.3% in the third quarter. Wells Fargo & Company MN now owns 5,944 shares of the company’s stock worth $110,000 after acquiring an additional 5,325 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Evolus by 761.4% during the second quarter. Tower Research Capital LLC TRC now owns 6,555 shares of the company’s stock valued at $183,000 after purchasing an additional 5,794 shares in the last quarter. TIAA CREF Investment Management LLC lifted its holdings in shares of Evolus by 51.2% during the third quarter. TIAA CREF Investment Management LLC now owns 12,259 shares of the company’s stock valued at $228,000 after purchasing an additional 4,151 shares in the last quarter. Finally, Man Group plc bought a new position in shares of Evolus during the third quarter valued at $232,000. 24.40% of the stock is currently owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

Further Reading: What is Liquidity?

Get a free copy of the Zacks research report on Evolus (EOLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.